CRISPR Therapeutics AG (NASDAQ:CRSP) Receives $73.11 Consensus PT from Analysts

Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) have been given a consensus recommendation of “Hold” by the twenty-one analysts that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, nine have given a hold recommendation and eleven have issued a buy recommendation on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $73.11.

Several research analysts recently commented on CRSP shares. Truist Financial boosted their price objective on shares of CRISPR Therapeutics from $100.00 to $120.00 and gave the stock a “buy” rating in a research note on Wednesday, February 12th. Stifel Nicolaus reduced their price target on CRISPR Therapeutics from $53.00 to $49.00 and set a “hold” rating on the stock in a research report on Thursday, February 13th. Bank of America lowered their price target on CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. Evercore ISI raised shares of CRISPR Therapeutics from an “in-line” rating to an “outperform” rating and raised their price target for the stock from $60.00 to $99.00 in a report on Friday, February 14th. Finally, JMP Securities reiterated a “market outperform” rating and set a $86.00 price objective on shares of CRISPR Therapeutics in a research note on Thursday, February 13th.

CRISPR Therapeutics Stock Up 14.7 %

Shares of NASDAQ:CRSP opened at $39.30 on Monday. The firm has a 50 day moving average of $41.14 and a 200 day moving average of $44.03. The company has a market capitalization of $3.37 billion, a price-to-earnings ratio of -8.99 and a beta of 1.85. CRISPR Therapeutics has a 52 week low of $30.04 and a 52 week high of $67.88.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Tuesday, February 11th. The company reported ($0.44) EPS for the quarter, topping the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. On average, sell-side analysts expect that CRISPR Therapeutics will post -5.16 EPS for the current year.

Insider Transactions at CRISPR Therapeutics

In related news, COO Julianne Bruno sold 1,198 shares of the company’s stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total value of $50,819.16. Following the completion of the transaction, the chief operating officer now owns 8,263 shares of the company’s stock, valued at approximately $350,516.46. This represents a 12.66 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, General Counsel James R. Kasinger sold 2,850 shares of the firm’s stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total value of $120,897.00. Following the completion of the sale, the general counsel now directly owns 77,530 shares in the company, valued at approximately $3,288,822.60. The trade was a 3.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 32,381 shares of company stock valued at $1,608,243 in the last 90 days. 4.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On CRISPR Therapeutics

A number of large investors have recently added to or reduced their stakes in CRSP. NBC Securities Inc. grew its position in shares of CRISPR Therapeutics by 156,300.0% in the first quarter. NBC Securities Inc. now owns 1,564 shares of the company’s stock valued at $53,000 after purchasing an additional 1,563 shares during the period. Green Alpha Advisors LLC boosted its holdings in CRISPR Therapeutics by 132.9% in the 1st quarter. Green Alpha Advisors LLC now owns 57,361 shares of the company’s stock worth $1,952,000 after buying an additional 32,732 shares during the last quarter. 180 Wealth Advisors LLC increased its stake in CRISPR Therapeutics by 22.9% during the 1st quarter. 180 Wealth Advisors LLC now owns 6,349 shares of the company’s stock worth $216,000 after buying an additional 1,182 shares in the last quarter. GAMMA Investing LLC raised its holdings in shares of CRISPR Therapeutics by 8,146.2% during the first quarter. GAMMA Investing LLC now owns 4,288 shares of the company’s stock valued at $146,000 after acquiring an additional 4,236 shares during the last quarter. Finally, AdvisorNet Financial Inc lifted its position in shares of CRISPR Therapeutics by 104.7% in the first quarter. AdvisorNet Financial Inc now owns 5,073 shares of the company’s stock valued at $173,000 after acquiring an additional 2,595 shares in the last quarter. 69.20% of the stock is currently owned by institutional investors and hedge funds.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.